In education for a client with type 2 diabetes starting an oral hypoglycemic, which statement should be addressed as a potential behavioral risk?

In education for a client with type 2 diabetes starting an oral hypoglycemic, which statement should be addressed as a potential behavioral risk?

• A. Oral hypoglycemics decrease absorption of carbohydrates
• B. Oral hypoglycemics stimulate insulin production
• C. Clients may subconsciously relax dietary rules to gain control
• D. Serious adverse effects are unlikely with these medications

Answer: (C)

Starting an oral hypoglycemic brings a behavioral risk into focus: the medication can give a sense of control that makes some people unconsciously loosen their dietary rules. Even when glucose-lowering pills are working well, diet and activity continue to drive overall control. If the patient relaxes meal plans, portions, or carbohydrate choices, glucose levels can drift higher or swing unpredictably, undermining treatment and potentially causing complications. Reinforce that medication and lifestyle work together—continue consistent meal planning, monitoring, and physical activity alongside the medicine. The other statements describe how the drugs work or their potential adverse effects rather than a behavioral risk. Some agents do stimulate insulin release or affect carbohydrate processing, and adverse effects can occur, but these are pharmacologic considerations rather than the behavioral risk at hand.

Starting an oral hypoglycemic brings a behavioral risk into focus: the medication can give a sense of control that makes some people unconsciously loosen their dietary rules. Even when glucose-lowering pills are working well, diet and activity continue to drive overall control. If the patient relaxes meal plans, portions, or carbohydrate choices, glucose levels can drift higher or swing unpredictably, undermining treatment and potentially causing complications. Reinforce that medication and lifestyle work together—continue consistent meal planning, monitoring, and physical activity alongside the medicine.

The other statements describe how the drugs work or their potential adverse effects rather than a behavioral risk. Some agents do stimulate insulin release or affect carbohydrate processing, and adverse effects can occur, but these are pharmacologic considerations rather than the behavioral risk at hand.